全国范围内整合多组学用于罕见病快速诊断
澳大利亚急性护理基因组学项目在2年内为290个疑似遗传病危重婴幼儿家庭提供全基因组测序,平均出结果时间2.9天,诊断率47%。对未确诊者追加生物信息分析、转录组测序及选做长读长测序和功能检测,额外确诊19例,总诊断率54%。120例(77%)确诊患者的重症管理发生改变。
要点
- 危重婴幼儿疑似遗传病全基因组测序平均2.9天出结果,诊断率47%。
- 追加多组学分析后额外确诊19例,总诊断率升至54%。
- 120例(77%)确诊患者的重症管理改变,94例(60%)为重大影响。
核心结论
- 整合多组学方法纳入主流诊断实践可及时实现罕见病基因组检测的潜力,结果提供初步临床效用证据。
研究设计与样本
- 急性护理基因组学项目在2年内为澳大利亚各地医院收治的290个疑似遗传病危重婴幼儿家庭提供全基因组测序。
- 对所有未确诊患者进行额外生物信息分析和转录组测序,并在选做病例中部署长读长测序和功能检测。
主要发现
- 平均出结果时间2.9天,诊断率47%。
- 额外生物信息分析、转录组测序及选做长读长测序和功能检测额外确诊19例,总诊断率54%。
- 诊断变异范围从结构染色体异常到内含子逆转录转座子破坏剪接。
- 120例确诊患者(77%)的重症管理发生改变,其中94例(60%)为重大影响,包括指导精准治疗、手术和移植决策及姑息治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Critically ill infants and children with rare diseases need equitable access to rapid and accurate diagnosis to direct clinical management. Over 2 years, the Acute Care Genomics program provided whole-genome sequencing to 290 families whose critically ill infants and children were admitted to hospitals throughout Australia with suspected genetic conditions. The average time to result was 2.9 d and diagnostic yield was 47%. We performed additional bioinformatic analyses and transcriptome sequencing in all patients who remained undiagnosed. Long-read sequencing and functional assays, ranging from clinically accredited enzyme analysis to bespoke quantitative proteomics, were deployed in selected cases. This resulted in an additional 19 diagnoses and an overall diagnostic yield of 54%. Diagnostic variants ranged from structural chromosomal abnormalities through to an intronic retrotransposon, disrupting splicing. Critical care management changed in 120 diagnosed patients (77%). This included major impacts, such as informing precision treatments, surgical and transplant decisions and palliation, in 94 patients (60%). Our results provide preliminary evidence of the clinical utility of integrating multi-omic approaches into mainstream diagnostic practice to fully realize the potential of rare disease genomic testing in a timely manner.
引用
- Lunke S, Bouffler SE, Patel CV, et al. Integrated multi-omics for rapid rare disease diagnosis on a national scale. Nat Med. 2023. PMID: 37291213. doi:10.1038/s41591-023-02401-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。